XCXu Chen

Xu Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xu Chen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Can Liu

    Department of Breast Surgery, Jinan Third People’s Hospital, Jinan, People’s Republic of China

    3 shared publications
  • Kai Zhang

    Department of Breast Surgery, General Surgery, Qilu Hospital of Shandong University

    3 shared publications
  • Lei Dong

    Department of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, People’s Republic of China

    3 shared publications
  • Peng Gao

    Department of Pathology, Qilu Hospital, Shandong University, Jinan, China

    3 shared publications
  • Yan-Yan Wang

    Center of Health Management, Qilu Hospital of Shandong University, Jinan, People’s Republic of China

    3 shared publications
  • Yuan Lin

    Department of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, People’s Republic of China

    3 shared publications

Latest Publications

  • miRNAs Associated with Axillary Lymph Node Metastasis in Breast Cancer: A Systematic Review and Meta-Analysis

    by Yuan Lin, Yan-Yan Wang, Zhi-Bao Xu, Lei Dong, Can Liu, Xu Chen, Kai Zhang

    Some microRNAs (miRNAs) may have potential as biomarkers for axillary lymph node metastasis (ALNM) in breast cancer. PubMed was systematically searched from its inception to October 2023 using the search term 'miRNA and breast cancer lymph node metastasis' to identify miRNAs reported in three or more relevant publications. Each qualifying miRNA was then paired with 'breast cancer' as search terms across four databases (PubMed, Embase, Web of Science, and Cochrane Library) covering the same time span. Studies investigating miRNA associations with ALNM in breast cancer were included and the evaluation indicators (odds ratio [OR]) or standardized mean difference [SMD]) were calculated. Nine miRNAs were frequently reported to be associated with breast cancer ALNM: miR-206, miR-21, miR-155, miR-124, miR-10b, miR-30a, miR-200c, miR-4521, and miR-101. Patients with high expression of miR-155 (OR 3.41 [1.92-6.06]) or low expression of miR-200c (OR 0.36 [0.17-0.77]) were more likely to experience ALNM. Compared with patients without lymph node metastasis, patients with positive ALNM had elevated expression levels of miR-21 (SMD 1.39 [0.66-2.13]), miR-155 (SMD 0.91 [0.17-1.65]), and miR-10b (SMD 0.63 [0.02-1.23]), and decreased expression levels of miR-200c (SMD - 0.44 [- 0.84 to - 0.05]) and miR-124 (SMD - 2.29 [- 3.93 to - 0.65]). High expression of miRNA-155, miRNA-21, and miRNA-10b, and low expression of miRNA-200c and miRNA-124, were significantly correlated with ALNM in breast cancer patients. miRNAs are expected to become biomarkers for predicting ALNM in breast cancer patients, although more clinical trials are needed for validation.


  • ASO Author Reflections: MicroRNAs as Predictive Biomarkers for Axillary Lymph Node Metastasis in Breast Cancer

    by Yuan Lin, Yan-Yan Wang, Zhi-Bao Xu, Lei Dong, Can Liu, Ya-Wen Wang, Xu Chen, Kai Zhang

  • Open Access

    PIN1P1 is activated by CREB1 and promotes gastric cancer progression via interacting with YBX1 and upregulating PIN1

    by Ya‐Wen Wang, Wen‐Jie Zhu, Ran‐Ran Ma, Ya‐Ru Tian, Xu Chen, Peng Gao

    Long noncoding RNAs (lncRNAs) play critical roles in the carcinogenesis and progression of cancers. However, the role and mechanism of the pseudogene lncRNA PIN1P1 in gastric carcinoma remain unclear. The expression and effects of lncRNA PIN1P1 in gastric cancer were investigated. The transcriptional regulation of CREB1 on PIN1P1 was determined by ChIP and luciferase assays. The mechanistic model of PIN1P1 in gastric cancer was further explored by RNA pull‐down, RIP and western blot analysis. PIN1P1 was overexpressed in gastric cancer tissues, and upregulated PIN1P1 predicted poor prognosis in patients. CREB1 was directly combined with the promoter region of PIN1P1 to promote the transcription of PIN1P1. CREB1‐mediated enhanced proliferation, migration and invasion could be partially reversed by downregulation of PIN1P1. Overexpressed PIN1P1 promoted the proliferation, migration and invasion of gastric cancer cells, whereas decreased PIN1P1 showed the opposite effects. PIN1P1 directly interacted with YBX1 and promoted YBX1 protein expression, leading to upregulation of PIN1, in which E2F1 may be involved. Silencing of YBX1 during PIN1P1 overexpression could partially rescue PIN1 upregulation. PIN1, the parental gene of PIN1P1, was elevated in gastric cancer tissues, and its upregulation was correlated with poor patient outcomes. PIN1 facilitated gastric cancer cell proliferation, migration and invasion. To sum up, CREB1‐activated PIN1P1 could promote gastric cancer progression through YBX1 and upregulating PIN1, suggesting that it is a potential target for gastric cancer.


  • Open Access

    Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response

    by Ai-Yan Xing, Bin Wang, Yu-Hong Li, Xu Chen, Ya-Wen Wang, Hai-Ting Liu, Peng Gao

    Background: Chemotherapy failure causes high breast cancer recurrence and poor patient prognosis. Thus, we studied a cohort of novel biomarkers to predict chemotherapeutic response in breast cancer. In this study, miRNA expression profiling was performed on 10 breast cancer punctured specimens sensitive to chemotherapy (MP grade 4, 5) and 10 chemotherapy resistant (MP grade 1). Differentially expressed miRNAs were verified by qRT-PCR in 60 initial samples, 59 validated samples and 71 independent samples. A miRNA signature was generated using a Logistic regression model. A receiver operating characteristic (ROC) test was used to assess specificity and sensitivity of single miRNA and miRNA signature. Target genes regulated by miRNAs and their involved signaling pathways were analyzed using GO enrichment and KEGG software. MiRNAs expression were separately compared with ER, PR, HER2 immunohistochemical staining and different drugs. qRT-PCR showed that the high expression of miR-23a-3p, miR-200c-3p, miR-214-3p and the low expression of miR-451a and miR-638 were closely related to chemoresistance. According to the formula for calculating the drug resistance risk, patients in the high-risk group were more likely to develop chemotherapy resistance than the low-risk group. Bioinformatics analysis showed that 5 miRNAs and target genes are mainly involved in p53, ubiquitin-mediated proteolysis, mTOR, Wnt, cells skeletal protein regulation, cell adhesion and ErbB signaling pathways. miR-451a expression was associated with ER, HER-2 status and anthracyclines. A miRNA signature of chemotherapeutic response may be clinically valuable for improving current chemotherapy regimens of individual treatment for patients with breast cancer.


  • Open Access

    SPIN1, negatively regulated by miR-148/152, enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer

    by Xu Chen, Ya-Wen Wang, Peng Gao

    Spindlin1 (SPIN1), a protein highly expressed in several human cancers, has been correlated with tumorigenesis and development. Alterations of drug metabolizing enzymes and drug transporters are major determinants of chemoresistance in tumor cells. However, whether the metabolizing enzymes and transporters are under the control of SPIN1 in breast cancer chemoresistance has not yet been defined. SPIN1 expression in breast cancer cells and tissues was detected by quantitative real-time PCR (qRT-PCR) and immunohistochemistry. Chemosensitivity assays in vitro and in vivo were performed to determine the effect of SPIN1 on Adriamycin resistance. Downstream effectors of SPIN1 were screened by microarray and confirmed by qRT-PCR and Western blot. Luciferase assay and Western blot were used to identify miRNAs regulating SPIN1. We showed that SPIN1 was significantly elevated in drug-resistant breast cancer cell lines and tissues, compared with the chemosensitive ones. SPIN1 enhanced Adriamycin resistance of breast cancer cells in vitro, and downregulation of SPIN1 by miRNA could decrease Adriamycin resistance in vivo. Mechanistically, drug metabolizing enzymes and transporter CYP2C8, UGT2B4, UGT2B17 and ABCB4 were proven to be downstream effectors of SPIN1. Notably, SPIN1 was identified as a direct target of the miR-148/152 family (miR-148a-3p, miR-148b-3p and miR-152-3p). As expected, miR-148a-3p, miR-148b-3p or miR-152-3p could increase Adriamycin sensitivity in breast cancer cells in vitro. Moreover, high expression of SPIN1 or low expression of the miR-148/152 family predicted poorer survival in breast cancer patients. Our results establish that SPIN1, negatively regulated by the miR-148/152 family, enhances Adriamycin resistance in breast cancer via upregulating the expression of drug metabolizing enzymes and drug transporter.